{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:27:24Z","timestamp":1768879644653,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T00:00:00Z","timestamp":1391126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10549-014-2844-7","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T09:03:13Z","timestamp":1391072593000},"page":"33-45","source":"Crossref","is-referenced-by-count":24,"title":["Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling"],"prefix":"10.1007","volume":"144","author":[{"given":"Zanjing","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"2844_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"R Coleman","year":"2001","unstructured":"Coleman R (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"2844_CR2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"2844_CR3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","volume":"88","author":"TA Guise","year":"2000","unstructured":"Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892\u20132898","journal-title":"Cancer"},{"key":"2844_CR4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"2844_CR5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","volume":"34","author":"GD Roodman","year":"2008","unstructured":"Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34:92\u2013101","journal-title":"Cancer Treat Rev"},{"key":"2844_CR6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1078-0432.162.11.1","volume":"11","author":"P Bhatia","year":"2005","unstructured":"Bhatia P, Sanders MM, Hansen MF (2005) Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11:162\u2013165","journal-title":"Clin Cancer Res"},{"key":"2844_CR7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.coph.2004.03.011","volume":"4","author":"E Leenheer De","year":"2004","unstructured":"De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI (2004) Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 4:340\u2013346","journal-title":"Curr Opin Pharmacol"},{"key":"2844_CR8","first-page":"5438","volume":"63","author":"AN Farrugia","year":"2003","unstructured":"Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC (2003) Receptor activator of nuclear factor-\u03baB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438\u20135445","journal-title":"Cancer Res"},{"key":"2844_CR9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","volume":"91","author":"ET Keller","year":"2004","unstructured":"Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718\u2013729","journal-title":"J Cell Biochem"},{"key":"2844_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"2844_CR11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15216540500137669","volume":"57","author":"X Feng","year":"2005","unstructured":"Feng X (2005) RANKing intracellular signaling in osteoclasts. IUBMB Life 57:389\u2013395","journal-title":"IUBMB Life"},{"key":"2844_CR12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jjco\/hys088","volume":"42","author":"T Kurata","year":"2012","unstructured":"Kurata T, Nakagawa K (2012) Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol 42:663\u2013669","journal-title":"Jpn J Clin Oncol"},{"key":"2844_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/ecp.12.35","volume":"5","author":"A Lipton","year":"2012","unstructured":"Lipton A, Balakumaran A (2012) Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Rev Clin Pharmacol 5:359\u2013371","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2844_CR14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/13543784.2012.679928","volume":"21","author":"M Mackiewicz-Wysocka","year":"2012","unstructured":"Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ (2012) Progress in the treatment of bone metastases in cancer patients. Expert Opin Invest Drugs 21:785\u2013795","journal-title":"Expert Opin Invest Drugs"},{"key":"2844_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/CIA.S27930","volume":"7","author":"CJ Paller","year":"2012","unstructured":"Paller CJ, Carducci MA, Philips GK (2012) Management of bone metastases in refractory prostate cancer\u2013role of denosumab. Clin Interv Aging 7:363","journal-title":"Clin Interv Aging"},{"key":"2844_CR16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378\u20131391","journal-title":"J Clin Oncol"},{"key":"2844_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-2004-818938","volume":"70","author":"E Ernst","year":"2004","unstructured":"Ernst E (2004) Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med 70:293\u2013298","journal-title":"Planta Med"},{"key":"2844_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0944-7113(97)80002-5","volume":"3","author":"J Melchior","year":"1997","unstructured":"Melchior J, Palm S, Wikman G (1997) Controlled clinical study of standardized Andrographis paniculata extract in common cold: a pilot trial. Phytomedicine 3:315\u2013318","journal-title":"Phytomedicine"},{"key":"2844_CR19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/med.20115","volume":"28","author":"AS Negi","year":"2008","unstructured":"Negi AS, Kumar J, Luqman S, Shanker K, Gupta M, Khanuja S (2008) Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 28:746\u2013772","journal-title":"Med Res Rev"},{"key":"2844_CR20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/np50097a002","volume":"56","author":"A Puri","year":"1993","unstructured":"Puri A, Saxena R, Saxena R, Saxena K, Srivastava V, Tandon J (1993) Immunostimulant agents from Andrographis paniculata. J Nat Prod 56:995\u2013999","journal-title":"J Nat Prod"},{"key":"2844_CR21","first-page":"25","volume":"12","author":"M Roxas","year":"2007","unstructured":"Roxas M, Jurenka J (2007) Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern Med Rev 12:25\u201348","journal-title":"Altern Med Rev"},{"key":"2844_CR22","first-page":"437","volume":"74","author":"V Thamlikitkul","year":"1991","unstructured":"Thamlikitkul V, Dechatiwongse T, Theerapong S, Chantrakul C, Boonroj P, Punkrut W, Ekpalakorn W, Boontaeng N, Taechaiya S, Petcharoen S (1991) Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai 74:437","journal-title":"J Med Assoc Thai"},{"key":"2844_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02887945","volume":"15","author":"G Zhi-ling","year":"1995","unstructured":"Zhi-ling G, Hua-yue Z, Xin-hua Z (1995) An experimental study of the mechanism of andrographis paniculata nees (APN) in alleviating the Ca(2+)-overloading in the process of myocardial ischemie reperfusion. J Tongji Med Univ 15:205\u2013208","journal-title":"J Tongji Med Univ"},{"key":"2844_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1359-4117.2003.01090.x","volume":"3","author":"S Rajagopal","year":"2003","unstructured":"Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R (2003) Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 3:147\u2013158","journal-title":"J Exp Ther Oncol"},{"key":"2844_CR25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1177\/0022034511418341","volume":"90","author":"L-J Wang","year":"2011","unstructured":"Wang L-J, Zhou X, Wang W, Tang F, Qi C-L, Yang X, Wu S, Lin Y-Q, Wang J-T, Geng J-G (2011) Andrographolide inhibits oral squamous cell carcinogenesis through NF-\u03baB inactivation. J Dent Res 90:1246\u20131252","journal-title":"J Dent Res"},{"key":"2844_CR26","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/np200631v","volume":"74","author":"H-W Chen","year":"2011","unstructured":"Chen H-W, Lin A-H, Chu H-C, Li C-C, Tsai C-W, Chao C-Y, Wang C-J, Lii C-K, Liu K-L (2011) Inhibition of TNF-\u03b1-induced inflammation by andrographolide via down-regulation of the PI3K\/Akt signaling pathway. J Nat Prod 74:2408\u20132413","journal-title":"J Nat Prod"},{"key":"2844_CR27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bjp.0702073","volume":"125","author":"WF Chiou","year":"1998","unstructured":"Chiou WF, Lin JJ, Chen CF (1998) Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide. Br J Pharmacol 125:327\u2013334","journal-title":"Br J Pharmacol"},{"key":"2844_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bjp.0704493","volume":"135","author":"YC Shen","year":"2002","unstructured":"Shen YC, Chen CF, Chiou WF (2002) Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism (s) involved in its anti-inflammatory effect. Br J Pharmacol 135:399\u2013406","journal-title":"Br J Pharmacol"},{"key":"2844_CR29","first-page":"284","volume":"92","author":"S Handa","year":"1990","unstructured":"Handa S, Sharma A (1990) Hepatoprotective activity of andrographolide against galactosamine and paracetamol intoxication in rats. Indian J Med Res 92:284","journal-title":"Indian J Med Res"},{"key":"2844_CR30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1534735409335606","volume":"8","author":"NP Trivedi","year":"2009","unstructured":"Trivedi NP, Rawal UM, Patel BP (2009) Potency of andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther 8:177\u2013189","journal-title":"Integr Cancer Ther"},{"key":"2844_CR31","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejmech.2008.12.014","volume":"44","author":"X Jiang","year":"2009","unstructured":"Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, Tian Z, Wright SC, Larrick JW, Wang Y (2009) Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur J Med Chem 44:2936\u20132943","journal-title":"Eur J Med Chem"},{"key":"2844_CR32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/92.14.1185a","volume":"92","author":"FR Miller","year":"2000","unstructured":"Miller FR, Santner SJ, Tait L, Dawson PJ (2000) MCF10DCIS. com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92:1185\u20131186","journal-title":"J Natl Cancer Inst"},{"key":"2844_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.23762","volume":"14","author":"P Nangia-Makker","year":"2013","unstructured":"Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A (2013) Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases. Cancer Biol Ther 14:1","journal-title":"Cancer Biol Ther"},{"key":"2844_CR34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ijc.22733","volume":"121","author":"P Nangia-Makker","year":"2007","unstructured":"Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A (2007) Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer 121:884\u2013894","journal-title":"Int J Cancer"},{"key":"2844_CR35","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ijc.22572","volume":"120","author":"LR Tait","year":"2007","unstructured":"Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, Miller FR (2007) Dynamic stromal-epithelial interactions during progression of MCF10DCIS. com xenografts. Int J Cancer 120:2127\u20132134","journal-title":"Int J Cancer"},{"key":"2844_CR36","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","volume":"96","author":"H Hsu","year":"1999","unstructured":"Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H-L, Elliott G, Kelley MJ, Sarosi I (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540\u20133545","journal-title":"Proc Natl Acad Sci USA"},{"key":"2844_CR37","doi-asserted-by":"crossref","first-page":"e34132","DOI":"10.1371\/journal.pone.0034132","volume":"7","author":"A Qin","year":"2012","unstructured":"Qin A, Cheng TS, Lin Z, Cao L, Chim SM, Pavlos NJ, Xu J, Zheng MH, Dai KR (2012) Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One 7:e34132","journal-title":"PLoS One"},{"key":"2844_CR38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1359\/jbmr.2003.18.12.2159","volume":"18","author":"C Wang","year":"2003","unstructured":"Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J (2003) 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-\u03baB activation. J Bone Miner Res 18:2159\u20132168","journal-title":"J Bone Miner Res"},{"key":"2844_CR39","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1073\/pnas.95.10.5795","volume":"95","author":"KT Akama","year":"1998","unstructured":"Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NF-\u03baB-dependent mechanism. Proc Natl Acad Sci USA 95:5795\u20135800","journal-title":"Proc Natl Acad Sci USA"},{"key":"2844_CR40","doi-asserted-by":"crossref","first-page":"18432","DOI":"10.1074\/jbc.M906304199","volume":"275","author":"JH Steer","year":"2000","unstructured":"Steer JH, Kroeger KM, Abraham LJ, Joyce DA (2000) Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappaB and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 275:18432\u201318440. doi: 10.1074\/jbc.M906304199","journal-title":"J Biol Chem"},{"key":"2844_CR41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00223-007-9077-2","volume":"81","author":"C Wedemeyer","year":"2007","unstructured":"Wedemeyer C, Xu J, Neuerburg C, Landgraeber S, Malyar NM, von Knoch F, Gosheger G, von Knoch M, L\u00f6er F, Saxler G (2007) Particle-induced osteolysis in three-dimensional micro-computed tomography. Calcif Tissue Int 81:394\u2013402","journal-title":"Calcif Tissue Int"},{"key":"2844_CR42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1006\/bbrc.1999.2008","volume":"267","author":"N Chikatsu","year":"2000","unstructured":"Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T (2000) Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632\u2013637","journal-title":"Biochem Biophys Res Commun"},{"key":"2844_CR43","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1101\/gad.11.24.3482","volume":"11","author":"G Franzoso","year":"1997","unstructured":"Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U (1997) Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482\u20133496","journal-title":"Genes Dev"},{"key":"2844_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2008.10.146","volume":"378","author":"N Soysa","year":"2009","unstructured":"Soysa N, Alles N (2009) NF-\u03baB functions in osteoclasts. Biochem Biophys Res Commun 378:1\u20135","journal-title":"Biochem Biophys Res Commun"},{"key":"2844_CR45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/41493","volume":"388","author":"JA DiDonato","year":"1997","unstructured":"DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive I\u03baB kinase that activates the transcription factor NF-\u03baB. Nature 388:548\u2013554","journal-title":"Nature"},{"key":"2844_CR46","doi-asserted-by":"crossref","first-page":"35081","DOI":"10.1074\/jbc.C500353200","volume":"280","author":"P Monje","year":"2005","unstructured":"Monje P, Hern\u00e1ndez-Losa J, Lyons RJ, Castellone MD, Gutkind JS (2005) Regulation of the transcriptional activity of c-Fos by ERK A novel role for the prolyl isomerase PIN1. J Biol Chem 280:35081\u201335084","journal-title":"J Biol Chem"},{"key":"2844_CR47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jcb.22800","volume":"112","author":"E Ang","year":"2011","unstructured":"Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H, Zheng MH, Xu J (2011) Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-\u03baB and ERK. J Cell Biochem 112:89\u201397","journal-title":"J Cell Biochem"},{"key":"2844_CR48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/mol.107.034173","volume":"72","author":"HJ Kim","year":"2007","unstructured":"Kim HJ, Lee Y, Chang E-J, Kim H-M, Hong S-P, Lee ZH, Ryu J, Kim H-H (2007) Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Mol Pharmacol 72:418\u2013428","journal-title":"Mol Pharmacol"},{"key":"2844_CR49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1172\/JCI200419657","volume":"114","author":"F Ikeda","year":"2004","unstructured":"Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J-I, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475\u2013484","journal-title":"J Clin Invest"},{"key":"2844_CR50","doi-asserted-by":"crossref","first-page":"31155","DOI":"10.1074\/jbc.M001229200","volume":"275","author":"M Matsumoto","year":"2000","unstructured":"Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-\u03baB ligand (RANKL). J Biol Chem 275:31155\u201331161","journal-title":"J Biol Chem"},{"key":"2844_CR51","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1242\/jcs.00082","volume":"115","author":"J-P David","year":"2002","unstructured":"David J-P, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF (2002) JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 115:4317\u20134325","journal-title":"J Cell Sci"},{"key":"2844_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/mol.109.057877","volume":"77","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Jin H, Shim H-E, Kim H-N, Ha H, Lee ZH (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-\u03baB signal. Mol Pharmacol 77:17\u201325","journal-title":"Mol Pharmacol"},{"key":"2844_CR53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S8756-3282(01)00657-3","volume":"30","author":"S Lee","year":"2002","unstructured":"Lee S, Woo K, Kim S, Kim H-M, Kwack K, Lee Z, Kim H-H (2002) The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30:71\u201377","journal-title":"Bone"},{"key":"2844_CR54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ni0302-221","volume":"3","author":"M Karin","year":"2002","unstructured":"Karin M, Lin A (2002) NF-\u03baB at the crossroads of life and death. Nat Immunol 3:221\u2013227","journal-title":"Nat Immunol"},{"key":"2844_CR55","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1038\/sj.onc.1207230","volume":"22","author":"J Kucharczak","year":"2003","unstructured":"Kucharczak J, Simmons MJ, Fan Y, Gelinas C (2003) To be, or not to be: NF-kappaB is the answer\u2013role of Rel\/NF-kappaB in the regulation of apoptosis. Oncogene 22:8961\u20138982. doi: 10.1038\/sj.onc.1207230","journal-title":"Oncogene"},{"key":"2844_CR56","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","volume":"18","author":"HL Pahl","year":"1999","unstructured":"Pahl HL (1999) Activators and target genes of Rel\/NF-kappaB transcription factors. Oncogene 18:6853","journal-title":"Oncogene"},{"key":"2844_CR57","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4049\/jimmunol.1201976","volume":"191","author":"C-L Chen","year":"2013","unstructured":"Chen C-L, Lin C-F, Wan S-W, Wei L-S, Chen M-C, Yeh T-M, Liu H-S, Anderson R, Lin Y-S (2013) Anti-dengue virus nonstructural protein 1 antibodies cause NO-mediated endothelial cell apoptosis via ceramide-regulated glycogen synthase kinase-3\u03b2 and NF-\u03baB activation. J Immunol 191:1744\u20131752","journal-title":"J Immunol"},{"issue":"Suppl","key":"2844_CR58","first-page":"81","volume":"109","author":"KM Ghosh Sankar","year":"2002","unstructured":"Ghosh Sankar KM (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):81\u201396","journal-title":"Cell"},{"key":"2844_CR59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1049\/iet-syb.2008.0172","volume":"3","author":"K Puszynski","year":"2009","unstructured":"Puszynski K, Bertolusso R, Lipniacki T (2009) Crosstalk between p53 and nuclear factor-\u03baB systems: pro-and anti-apoptotic functions of NF-\u03baB. IET Syst Biol 3:356\u2013367","journal-title":"IET Syst Biol"},{"key":"2844_CR60","first-page":"53","volume":"1766","author":"SK Radhakrishnan","year":"2006","unstructured":"Radhakrishnan SK, Kamalakaran S (2006) Pro-apoptotic role of NF-\u03baB: implications for cancer therapy. Biochim Biophys Acta 1766:53\u201362","journal-title":"Biochim Biophys Acta"},{"key":"2844_CR61","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647\u2013656","journal-title":"Nat Rev Cancer"},{"key":"2844_CR62","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1002\/j.1460-2075.1995.tb00305.x","volume":"14","author":"Y Emoto","year":"1995","unstructured":"Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong W, Kamen R, Weichselbaum R (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148","journal-title":"EMBO J"},{"key":"2844_CR63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","volume":"6","author":"AG Porter","year":"1999","unstructured":"Porter AG, J\u00e4nicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99","journal-title":"Cell Death Differ"},{"key":"2844_CR64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1101\/gad.10.9.1073","volume":"10","author":"D Xue","year":"1996","unstructured":"Xue D, Shaham S, Horvitz HR (1996) The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 10:1073\u20131083","journal-title":"Genes Dev"},{"key":"2844_CR65","volume-title":"Global cancer facts and figures\u00a02007","author":"M Garcia","year":"2007","unstructured":"Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, Thun M (2007) Global cancer facts and figures\u00a02007. American Cancer Society, Atlanta"},{"key":"2844_CR66","volume-title":"Breast cancer facts and figures\u00a02007\u20132008","author":"Society AC","year":"2007","unstructured":"Society AC (2007) Breast cancer facts and figures\u00a02007\u20132008. American Cancer Society, Atlanta"},{"key":"2844_CR67","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","volume":"77","author":"R Coleman","year":"1998","unstructured":"Coleman R, Smith P, Rubens R (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77:336","journal-title":"Br J Cancer"},{"key":"2844_CR68","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588\u20131594","journal-title":"Cancer"},{"key":"2844_CR69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ncponc1323","volume":"6","author":"L Costa","year":"2009","unstructured":"Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163\u2013174","journal-title":"Nat Clin Pract Oncol"},{"key":"2844_CR70","doi-asserted-by":"crossref","first-page":"75S","DOI":"10.1016\/S8756-3282(02)00715-9","volume":"30","author":"J Body","year":"2002","unstructured":"Body J (2002) Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30:75S","journal-title":"Bone"},{"key":"2844_CR71","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.SMJ.0000051146.93190.4A","volume":"96","author":"SG Haskell","year":"2003","unstructured":"Haskell SG (2003) Selective estrogen receptor modulators. South Med J 96:469\u2013476","journal-title":"South Med J"},{"key":"2844_CR72","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508\u20131514","journal-title":"Science"},{"issue":"28","key":"2844_CR73","first-page":"1323","volume":"31","author":"F Tremollieres","year":"2002","unstructured":"Tremollieres F, Lopes P (2002) Specific estrogen receptor modulators (SERMs). Presse Med 31(28):1323\u20131328","journal-title":"Presse Med"},{"key":"2844_CR74","doi-asserted-by":"crossref","unstructured":"Watts NB (2003) Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19(2):395\u2013414","DOI":"10.1016\/S0749-0690(02)00069-1"},{"key":"2844_CR75","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","volume":"338","author":"AJJ Wood","year":"1998","unstructured":"Wood AJJ, Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736\u2013746","journal-title":"N Engl J Med"},{"key":"2844_CR76","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","volume":"72","author":"A Mariotti","year":"2008","unstructured":"Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72:919\u2013929","journal-title":"J Dent Educ"},{"key":"2844_CR77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MOO.0b013e328304b445","volume":"16","author":"A Gevorgyan","year":"2008","unstructured":"Gevorgyan A, Enepekides DJ (2008) Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare. Curr Opin Otolaryngol Head Neck Surg 16:325\u2013330","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2844_CR78","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla S (2001) Minireview: the OPG\/RANKL\/RANK system. Endocrinology 142:5050\u20135055","journal-title":"Endocrinology"},{"key":"2844_CR79","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bone.2010.03.001","volume":"46","author":"J Canon","year":"2010","unstructured":"Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC (2010) Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46:1613\u20131619","journal-title":"Bone"},{"key":"2844_CR80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119\u2013129","journal-title":"Clin Exp Metastasis"},{"key":"2844_CR81","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432\u20134436","journal-title":"Cancer Res"},{"key":"2844_CR82","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","volume":"4","author":"SL Teitelbaum","year":"2003","unstructured":"Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638\u2013649","journal-title":"Nat Rev Genet"},{"key":"2844_CR83","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm1197-1285","volume":"3","author":"V Iotsova","year":"1997","unstructured":"Iotsova V, Caama\u00f1o J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-\u03baB1 and NF-\u03baB2. Nat Med 3:1285\u20131289","journal-title":"Nat Med"},{"key":"2844_CR84","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1359\/jbmr.2002.17.7.1200","volume":"17","author":"L Xing","year":"2002","unstructured":"Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF (2002) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17:1200\u20131210. doi: 10.1359\/jbmr.2002.17.7.1200","journal-title":"J Bone Miner Res"},{"key":"2844_CR85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-0-387-72009-8_16","volume":"602","author":"MG Ruocco","year":"2007","unstructured":"Ruocco MG, Karin M (2007) Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. Adv Exp Med Biol 602:125\u2013134","journal-title":"Adv Exp Med Biol"},{"key":"2844_CR86","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.20042081","volume":"201","author":"MG Ruocco","year":"2005","unstructured":"Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu L-C, Cao Y, Schett G, Wagner EF, Karin M (2005) I\u03baB kinase (IKK) \u03b2, but not IKK\u03b1, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677\u20131687","journal-title":"J Exp Med"},{"key":"2844_CR87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-291X(03)00695-8","volume":"305","author":"ZH Lee","year":"2003","unstructured":"Lee ZH, Kim H-H (2003) Signal transduction by receptor activator of nuclear factor kappaB in osteoclasts. Biochem Biophys Res Commun 305:211\u2013214","journal-title":"Biochem Biophys Res Commun"},{"key":"2844_CR88","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.1073\/pnas.0403621101","volume":"101","author":"DK Biswas","year":"2004","unstructured":"Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-\u03baB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:10137\u201310142","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2844-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2844-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2844-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:12:26Z","timestamp":1688962346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2844-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2844-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}